For strain engineers developing novel pathways, pathway feasibility starts long before host engineering. Enzyme discovery, substrate compatibility, cofactor requirements, and IP freedom-to- operate can determine whether a pathway is commercially viable or blocked by technical constraints. Still, enzyme evaluation is often overlooked during early strain design, resulting in costly redesign cycles later in development.

At Aminoverse, we support pathway discovery with an enzyme-first strategy. By combining sequence mining, functional annotation, and IP liberty analysis, we help identify enzymes and pathway variants that are both biologically relevant and commercially actionable. This enables strain engineering teams to de-risk pathway construction before investing in extensive chassis optimization trials.

Here, we prevented a customer from a year-long strain and enzyme development campaign. They requested a professional feasibility assessment of the compatibility of their chosen enzyme with the overall pathway. While the chemistry made absolute sense, we flagged an expected co-factor imbalance that had a high likelihood of impeding product yields.

When considering your next pathway establishment in your strain, you can benefit from:

• Feasibility assessment of planned enzymatic pathways
• Identification of suitable or alternative enzyme candidates with improved performance
profile, e.g., substrate specificity, co-factor preference or inhibitory kinetics
• Early-stage freedom-to-operate assessment for key enzymatic steps
• Functional comparison of homologs across microbial species
• Prioritization of pathway variants with reduced metabolic burden or improved redox balance
• Recommendations for enzyme combinations compatible with the production host